Q-omics provides the consensus-scored TUBBP9 profile across patient tissues and cancer cell-line models. TUBBP9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TUBBP9 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, TUBBP9 RNA expression shows 5,474 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, and BRCA as cancer lineages where TUBBP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBBP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBBP9 survival associations across molecular data types. TUBBP9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBBP9 RNA expression–survival associations across cancer types. High TUBBP9 expression shows unfavorable associations in STAD, THCA, KIRP and READ, but favorable associations in LUSC and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for TUBBP9 RNA expression.
This table summarizes TUBBP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TUBBP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBBP9 shows lower tumor expression in BRCA, THCA, LUAD, KIRP and LUSC and higher tumor expression in LIHC. The BRCA box plot shows higher TUBBP9 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p < 0.001).
This table shows molecular features associated with TUBBP9 in patient tissues and cancer cell lines. In patient samples, TUBBP9 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
